Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, this warning letter was issued to Lijiang Yinghua Biochemical and Pharmaceutical Co., Ltd., a pharmaceutical manufacturer, on April 19, 2018. Without access to the full letter text or specific subject line details, the precise nature of the violations cannot be determined from the available information. The warning letter addresses an "Other" product category, suggesting the violations may fall outside standard drug or device classifications. Further documentation review would be necessary to identify the specific regulatory compliance issues and affected products.